Friday, 16 October 2026European Markets

IDEX BIOMETRICS Stock Went Up By Over 12% So Far Today

Loading stream...

(VIANEWS) - Shares of IDEX BIOMETRICS (Oslo Børs Benchmark Index_GI: IDEX.OL) rose by a staggering 12.14% to kr0.97 at 13:38 EST on Wednesday, after two sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI is rising 0.2% to kr1,243.41, following the last session's upward trend. This seems, up to now, a somewhat up trend trading session today.

IDEX BIOMETRICS's last close was kr0.85, 61.26% below its 52-week high of kr2.19.

About IDEX BIOMETRICS

IDEX Biometrics ASA engages in the design, development, and sale of fingerprint authentication solutions in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's fingerprint authentication solutions are used primarily in contactless financial payment, access control, and smart cards, as well as card-based devices for the storage of digital currencies. It primarily serves manufacturers of smart cards for financial payment applications and biometric payment card markets. IDEX Biometrics ASA was incorporated in 1996 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, IDEX BIOMETRICS has a trailing twelve months EPS of kr-0.51.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -107.86%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, IDEX BIOMETRICS's stock is considered to be overbought (>=80).

Earnings Before Interest, Taxes, Depreciation, and Amortization

IDEX BIOMETRICS's EBITDA is -68.72.

Volume

Today's last reported volume for IDEX BIOMETRICS is 4450088 which is 8.75% below its average volume of 4876880.

More news about IDEX BIOMETRICS (IDEX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com